Antibodies targeting PD-1 and PD-L1 are active in multiple malignancies and TGA and PBS approved for the treatment of melanoma, non-small cell lung cancer and renal cell carcinoma. Despite this activity there are tumour types where these agents have little activity and even in melanoma at least 40% of patients will have no benefit from single agent anti-PD1 agents. Further the development of acquired resistance to anti-PD1 is an increasingly recognized problem. Novel combinations are currently under development with a view to overcoming both innate and acquired resistance to anti-PD1/PDL1 agents. This presentation will present preclinical and clinical data of novel immunotherapeutic agents.